dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2021-06-25T11:09:54Z
dc.date.accessioned2022-12-19T22:39:15Z
dc.date.available2021-06-25T11:09:54Z
dc.date.available2022-12-19T22:39:15Z
dc.date.created2021-06-25T11:09:54Z
dc.date.issued2021-01-01
dc.identifierLasers in Medical Science.
dc.identifier1435-604X
dc.identifier0268-8921
dc.identifierhttp://hdl.handle.net/11449/208296
dc.identifier10.1007/s10103-020-03234-5
dc.identifier2-s2.0-85098982902
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5388893
dc.description.abstractThis study aimed to investigate the effects of administering photobiomodulation therapy (PBM) with bovine bone matrix on critical size defects in rats. Seventy-two adult male rats (albinus, Wistar), 90 days old, were used. Defect of 5 mm in diameter was made in their calvaria. The animals were divided into 4 groups: C-blood clot, B-Bio-Oss®, L-PBM, B+L-Bio-Oss®+PBM. Each group has been subdivided into 07, 30, and 60 days of observation. For PBM, a low GaAlAs energy of 660 nm was irradiated, total energy density of 45 J/cm2. PBM was conducted in a trans-surgical form once only. For immunohistochemistry, a semi-quantitative analysis was made of expression of osteoprotegerin (OPG), nuclear kappa B-factor ligand receptor activator (RANKL), and tartrate-resistant acid phosphatase (TRAP). All histomorphometric data were statistically analyzed by ANOVA and Tukey test, significance level of 5%. The groups that showed the highest proportion of neoformation were L (0.39% ± 0.13) and C (0.37% ± 0.97), but groups B and B+L had larger defect size (C-1.75 mm2 ± 0.40, B-3.02 mm2 ± 0.63, L-2.45 mm2 ± 0.53, B+L-3.23 mm2 ± 1.01). In immunohistochemistry, groups B and B+L had higher immunostaining scores for OPG and RANKL at 60 days, and TRAP immunostaining increased in all groups at 30 days, but group L was the only one to present specimens with score 0. Although, at 60 days, groups L and C presented the highest proportion of bone neoformation, at 30 days group B+L had more than twice as much bone neoformation as group B, the choice of treatment application should depend on the aim of the treatment.
dc.languageeng
dc.relationLasers in Medical Science
dc.sourceScopus
dc.subjectBiocompatible materials
dc.subjectBone regeneration
dc.subjectBone transplantation
dc.subjectImmunohistochemistry
dc.subjectLow-level light therapy
dc.titleBone repair assessment of critical size defects in rats treated with mineralized bovine bone (Bio-Oss®) and photobiomodulation therapy: a histomorphometric and immunohistochemical study
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución